Prognostic significance of adjuvant therapy and specific radiation dosages in Taiwanese patients with oral cavity cancer and extra-nodal extension: a nationwide cohort study
The evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in National Comprehensive Cancer Network (NCCN) guidelines is derived from patients with head and neck cancer. The guidelines further suggest a radiation dose ranging fro...
Saved in:
| Published in | BMC cancer Vol. 24; no. 1; pp. 1320 - 12 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
25.10.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in National Comprehensive Cancer Network (NCCN) guidelines is derived from patients with head and neck cancer. The guidelines further suggest a radiation dose ranging from 6000 to 6600 cGy. In this nationwide study, we sought to evaluate the prognostic significance of adjuvant therapy and the specific radiation dosage in Taiwanese patients with pure OCSCC and ENE.
A retrospective analysis of 1577 OCSCC patients with ENE who underwent resection and received adjuvant CRT or radiotherapy (RT) between January 2011 and December 2020 was conducted.
Multivariable analysis revealed that adjuvant RT, more than four pathologically positive nodes, and radiation dosage below 6000 cGy were independent risk factors for unfavorable 5-year disease-specific survival (DSS) and overall survival (OS). Comparing patients who received CRT (n = 1453) to those treated with RT (n = 124) before and after propensity score (PS) matching, the 5-year outcomes were as follows: before PS matching, DSS (54% versus 30%, p < 0.0001), OS (42% versus 18%, p < 0.0001); after PS matching (n = 111 in each group), DSS (52% versus 30%, p = 0.0016), OS (38% versus 21%, p = 0.0019). For patients who underwent CRT, the 5-year outcomes for different radiation dose groups (6600 - 7000 cGy, n = 1155 versus 6000 - 6500 cGy, n = 199) were as follows: before PS matching, DSS (52% versus 54%, p = 0.1904), OS (43% versus 46%, p = 0.1610); after PS matching (n = 199 in each group), DSS (55% versus 54%, p = 0.8374), OS (46.5% versus 46.3%, p = 0.7578).
For OCSCC patients with ENE, our study shows CRT improved survivals than RT alone, underscoring the clinical significance of chemotherapy. Patients undergoing CRT with irradiation doses ranging from 6000 to 6500 cGy exhibited comparable survival outcomes to those receiving doses of 6600-7000 cGy. This observation suggests that irradiation doses exceeding the 6600 cGy may not confer the survival advantage in these patients. Further research is needed to confirm our results and explore the optimal irradiation dose for managing these patients. |
|---|---|
| AbstractList | Background The evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in National Comprehensive Cancer Network (NCCN) guidelines is derived from patients with head and neck cancer. The guidelines further suggest a radiation dose ranging from 6000 to 6600 cGy. In this nationwide study, we sought to evaluate the prognostic significance of adjuvant therapy and the specific radiation dosage in Taiwanese patients with pure OCSCC and ENE. Methods A retrospective analysis of 1577 OCSCC patients with ENE who underwent resection and received adjuvant CRT or radiotherapy (RT) between January 2011 and December 2020 was conducted. Results Multivariable analysis revealed that adjuvant RT, more than four pathologically positive nodes, and radiation dosage below 6000 cGy were independent risk factors for unfavorable 5-year disease-specific survival (DSS) and overall survival (OS). Comparing patients who received CRT (n = 1453) to those treated with RT (n = 124) before and after propensity score (PS) matching, the 5-year outcomes were as follows: before PS matching, DSS (54% versus 30%, p < 0.0001), OS (42% versus 18%, p < 0.0001); after PS matching (n = 111 in each group), DSS (52% versus 30%, p = 0.0016), OS (38% versus 21%, p = 0.0019). For patients who underwent CRT, the 5-year outcomes for different radiation dose groups (6600 - 7000 cGy, n = 1155 versus 6000 - 6500 cGy, n = 199) were as follows: before PS matching, DSS (52% versus 54%, p = 0.1904), OS (43% versus 46%, p = 0.1610); after PS matching (n = 199 in each group), DSS (55% versus 54%, p = 0.8374), OS (46.5% versus 46.3%, p = 0.7578). Conclusions For OCSCC patients with ENE, our study shows CRT improved survivals than RT alone, underscoring the clinical significance of chemotherapy. Patients undergoing CRT with irradiation doses ranging from 6000 to 6500 cGy exhibited comparable survival outcomes to those receiving doses of 6600-7000 cGy. This observation suggests that irradiation doses exceeding the 6600 cGy may not confer the survival advantage in these patients. Further research is needed to confirm our results and explore the optimal irradiation dose for managing these patients. Keywords: Oral cavity squamous cell carcinoma, Extra-nodal extension, Chemoradiotherapy, Radiotherapy, Cancer registry, Survival outcomes The evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in National Comprehensive Cancer Network (NCCN) guidelines is derived from patients with head and neck cancer. The guidelines further suggest a radiation dose ranging from 6000 to 6600 cGy. In this nationwide study, we sought to evaluate the prognostic significance of adjuvant therapy and the specific radiation dosage in Taiwanese patients with pure OCSCC and ENE. A retrospective analysis of 1577 OCSCC patients with ENE who underwent resection and received adjuvant CRT or radiotherapy (RT) between January 2011 and December 2020 was conducted. Multivariable analysis revealed that adjuvant RT, more than four pathologically positive nodes, and radiation dosage below 6000 cGy were independent risk factors for unfavorable 5-year disease-specific survival (DSS) and overall survival (OS). Comparing patients who received CRT (n = 1453) to those treated with RT (n = 124) before and after propensity score (PS) matching, the 5-year outcomes were as follows: before PS matching, DSS (54% versus 30%, p < 0.0001), OS (42% versus 18%, p < 0.0001); after PS matching (n = 111 in each group), DSS (52% versus 30%, p = 0.0016), OS (38% versus 21%, p = 0.0019). For patients who underwent CRT, the 5-year outcomes for different radiation dose groups (6600 - 7000 cGy, n = 1155 versus 6000 - 6500 cGy, n = 199) were as follows: before PS matching, DSS (52% versus 54%, p = 0.1904), OS (43% versus 46%, p = 0.1610); after PS matching (n = 199 in each group), DSS (55% versus 54%, p = 0.8374), OS (46.5% versus 46.3%, p = 0.7578). For OCSCC patients with ENE, our study shows CRT improved survivals than RT alone, underscoring the clinical significance of chemotherapy. Patients undergoing CRT with irradiation doses ranging from 6000 to 6500 cGy exhibited comparable survival outcomes to those receiving doses of 6600-7000 cGy. This observation suggests that irradiation doses exceeding the 6600 cGy may not confer the survival advantage in these patients. Further research is needed to confirm our results and explore the optimal irradiation dose for managing these patients. The evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in National Comprehensive Cancer Network (NCCN) guidelines is derived from patients with head and neck cancer. The guidelines further suggest a radiation dose ranging from 6000 to 6600 cGy. In this nationwide study, we sought to evaluate the prognostic significance of adjuvant therapy and the specific radiation dosage in Taiwanese patients with pure OCSCC and ENE. A retrospective analysis of 1577 OCSCC patients with ENE who underwent resection and received adjuvant CRT or radiotherapy (RT) between January 2011 and December 2020 was conducted. Multivariable analysis revealed that adjuvant RT, more than four pathologically positive nodes, and radiation dosage below 6000 cGy were independent risk factors for unfavorable 5-year disease-specific survival (DSS) and overall survival (OS). Comparing patients who received CRT (n = 1453) to those treated with RT (n = 124) before and after propensity score (PS) matching, the 5-year outcomes were as follows: before PS matching, DSS (54% versus 30%, p < 0.0001), OS (42% versus 18%, p < 0.0001); after PS matching (n = 111 in each group), DSS (52% versus 30%, p = 0.0016), OS (38% versus 21%, p = 0.0019). For patients who underwent CRT, the 5-year outcomes for different radiation dose groups (6600 - 7000 cGy, n = 1155 versus 6000 - 6500 cGy, n = 199) were as follows: before PS matching, DSS (52% versus 54%, p = 0.1904), OS (43% versus 46%, p = 0.1610); after PS matching (n = 199 in each group), DSS (55% versus 54%, p = 0.8374), OS (46.5% versus 46.3%, p = 0.7578). For OCSCC patients with ENE, our study shows CRT improved survivals than RT alone, underscoring the clinical significance of chemotherapy. Patients undergoing CRT with irradiation doses ranging from 6000 to 6500 cGy exhibited comparable survival outcomes to those receiving doses of 6600-7000 cGy. This observation suggests that irradiation doses exceeding the 6600 cGy may not confer the survival advantage in these patients. Further research is needed to confirm our results and explore the optimal irradiation dose for managing these patients. The evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in National Comprehensive Cancer Network (NCCN) guidelines is derived from patients with head and neck cancer. The guidelines further suggest a radiation dose ranging from 6000 to 6600 cGy. In this nationwide study, we sought to evaluate the prognostic significance of adjuvant therapy and the specific radiation dosage in Taiwanese patients with pure OCSCC and ENE.BACKGROUNDThe evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in National Comprehensive Cancer Network (NCCN) guidelines is derived from patients with head and neck cancer. The guidelines further suggest a radiation dose ranging from 6000 to 6600 cGy. In this nationwide study, we sought to evaluate the prognostic significance of adjuvant therapy and the specific radiation dosage in Taiwanese patients with pure OCSCC and ENE.A retrospective analysis of 1577 OCSCC patients with ENE who underwent resection and received adjuvant CRT or radiotherapy (RT) between January 2011 and December 2020 was conducted.METHODSA retrospective analysis of 1577 OCSCC patients with ENE who underwent resection and received adjuvant CRT or radiotherapy (RT) between January 2011 and December 2020 was conducted.Multivariable analysis revealed that adjuvant RT, more than four pathologically positive nodes, and radiation dosage below 6000 cGy were independent risk factors for unfavorable 5-year disease-specific survival (DSS) and overall survival (OS). Comparing patients who received CRT (n = 1453) to those treated with RT (n = 124) before and after propensity score (PS) matching, the 5-year outcomes were as follows: before PS matching, DSS (54% versus 30%, p < 0.0001), OS (42% versus 18%, p < 0.0001); after PS matching (n = 111 in each group), DSS (52% versus 30%, p = 0.0016), OS (38% versus 21%, p = 0.0019). For patients who underwent CRT, the 5-year outcomes for different radiation dose groups (6600 - 7000 cGy, n = 1155 versus 6000 - 6500 cGy, n = 199) were as follows: before PS matching, DSS (52% versus 54%, p = 0.1904), OS (43% versus 46%, p = 0.1610); after PS matching (n = 199 in each group), DSS (55% versus 54%, p = 0.8374), OS (46.5% versus 46.3%, p = 0.7578).RESULTSMultivariable analysis revealed that adjuvant RT, more than four pathologically positive nodes, and radiation dosage below 6000 cGy were independent risk factors for unfavorable 5-year disease-specific survival (DSS) and overall survival (OS). Comparing patients who received CRT (n = 1453) to those treated with RT (n = 124) before and after propensity score (PS) matching, the 5-year outcomes were as follows: before PS matching, DSS (54% versus 30%, p < 0.0001), OS (42% versus 18%, p < 0.0001); after PS matching (n = 111 in each group), DSS (52% versus 30%, p = 0.0016), OS (38% versus 21%, p = 0.0019). For patients who underwent CRT, the 5-year outcomes for different radiation dose groups (6600 - 7000 cGy, n = 1155 versus 6000 - 6500 cGy, n = 199) were as follows: before PS matching, DSS (52% versus 54%, p = 0.1904), OS (43% versus 46%, p = 0.1610); after PS matching (n = 199 in each group), DSS (55% versus 54%, p = 0.8374), OS (46.5% versus 46.3%, p = 0.7578).For OCSCC patients with ENE, our study shows CRT improved survivals than RT alone, underscoring the clinical significance of chemotherapy. Patients undergoing CRT with irradiation doses ranging from 6000 to 6500 cGy exhibited comparable survival outcomes to those receiving doses of 6600-7000 cGy. This observation suggests that irradiation doses exceeding the 6600 cGy may not confer the survival advantage in these patients. Further research is needed to confirm our results and explore the optimal irradiation dose for managing these patients.CONCLUSIONSFor OCSCC patients with ENE, our study shows CRT improved survivals than RT alone, underscoring the clinical significance of chemotherapy. Patients undergoing CRT with irradiation doses ranging from 6000 to 6500 cGy exhibited comparable survival outcomes to those receiving doses of 6600-7000 cGy. This observation suggests that irradiation doses exceeding the 6600 cGy may not confer the survival advantage in these patients. Further research is needed to confirm our results and explore the optimal irradiation dose for managing these patients. Abstract Background The evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in National Comprehensive Cancer Network (NCCN) guidelines is derived from patients with head and neck cancer. The guidelines further suggest a radiation dose ranging from 6000 to 6600 cGy. In this nationwide study, we sought to evaluate the prognostic significance of adjuvant therapy and the specific radiation dosage in Taiwanese patients with pure OCSCC and ENE. Methods A retrospective analysis of 1577 OCSCC patients with ENE who underwent resection and received adjuvant CRT or radiotherapy (RT) between January 2011 and December 2020 was conducted. Results Multivariable analysis revealed that adjuvant RT, more than four pathologically positive nodes, and radiation dosage below 6000 cGy were independent risk factors for unfavorable 5-year disease-specific survival (DSS) and overall survival (OS). Comparing patients who received CRT (n = 1453) to those treated with RT (n = 124) before and after propensity score (PS) matching, the 5-year outcomes were as follows: before PS matching, DSS (54% versus 30%, p < 0.0001), OS (42% versus 18%, p < 0.0001); after PS matching (n = 111 in each group), DSS (52% versus 30%, p = 0.0016), OS (38% versus 21%, p = 0.0019). For patients who underwent CRT, the 5-year outcomes for different radiation dose groups (6600 − 7000 cGy, n = 1155 versus 6000 − 6500 cGy, n = 199) were as follows: before PS matching, DSS (52% versus 54%, p = 0.1904), OS (43% versus 46%, p = 0.1610); after PS matching (n = 199 in each group), DSS (55% versus 54%, p = 0.8374), OS (46.5% versus 46.3%, p = 0.7578). Conclusions For OCSCC patients with ENE, our study shows CRT improved survivals than RT alone, underscoring the clinical significance of chemotherapy. Patients undergoing CRT with irradiation doses ranging from 6000 to 6500 cGy exhibited comparable survival outcomes to those receiving doses of 6600–7000 cGy. This observation suggests that irradiation doses exceeding the 6600 cGy may not confer the survival advantage in these patients. Further research is needed to confirm our results and explore the optimal irradiation dose for managing these patients. BackgroundThe evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in National Comprehensive Cancer Network (NCCN) guidelines is derived from patients with head and neck cancer. The guidelines further suggest a radiation dose ranging from 6000 to 6600 cGy. In this nationwide study, we sought to evaluate the prognostic significance of adjuvant therapy and the specific radiation dosage in Taiwanese patients with pure OCSCC and ENE.MethodsA retrospective analysis of 1577 OCSCC patients with ENE who underwent resection and received adjuvant CRT or radiotherapy (RT) between January 2011 and December 2020 was conducted.ResultsMultivariable analysis revealed that adjuvant RT, more than four pathologically positive nodes, and radiation dosage below 6000 cGy were independent risk factors for unfavorable 5-year disease-specific survival (DSS) and overall survival (OS). Comparing patients who received CRT (n = 1453) to those treated with RT (n = 124) before and after propensity score (PS) matching, the 5-year outcomes were as follows: before PS matching, DSS (54% versus 30%, p < 0.0001), OS (42% versus 18%, p < 0.0001); after PS matching (n = 111 in each group), DSS (52% versus 30%, p = 0.0016), OS (38% versus 21%, p = 0.0019). For patients who underwent CRT, the 5-year outcomes for different radiation dose groups (6600 − 7000 cGy, n = 1155 versus 6000 − 6500 cGy, n = 199) were as follows: before PS matching, DSS (52% versus 54%, p = 0.1904), OS (43% versus 46%, p = 0.1610); after PS matching (n = 199 in each group), DSS (55% versus 54%, p = 0.8374), OS (46.5% versus 46.3%, p = 0.7578).ConclusionsFor OCSCC patients with ENE, our study shows CRT improved survivals than RT alone, underscoring the clinical significance of chemotherapy. Patients undergoing CRT with irradiation doses ranging from 6000 to 6500 cGy exhibited comparable survival outcomes to those receiving doses of 6600–7000 cGy. This observation suggests that irradiation doses exceeding the 6600 cGy may not confer the survival advantage in these patients. Further research is needed to confirm our results and explore the optimal irradiation dose for managing these patients. |
| ArticleNumber | 1320 |
| Audience | Academic |
| Author | Tsai, Yao-Te Hsieh, Chia-Hsun Huang, Shiang-Fu Chien, Chih-Yen Hsin, Li-Jen Tsao, Chung-Kan Wang, Yu-Chien Lee, Li-Ang Lin, Wan-Ni Hua, Chun-Hung Wang, Hung-Ming Yen, Tzu-Chen Kang, Chung-Jan Wen, Yu-Wen Terng, Shyuang-Der Lin, Chien-Yu Fan, Kang-Hsing Lin, Chih-Hung Fang, Tuan-Jen Chen, Wen-Cheng Ng, Shu-Hang Fang, Ku-Hao Liao, Chun-Ta Yeh, Chih-Hua Lin, Jin-Ching Chen, Tsung-Ming Tsai, Chi-Ying Lee, Shu-Ru Cheng, Nai-Ming Lee, Li-Yu Wang, Cheng Ping |
| Author_xml | – sequence: 1 givenname: Yao-Te surname: Tsai fullname: Tsai, Yao-Te – sequence: 2 givenname: Wen-Cheng surname: Chen fullname: Chen, Wen-Cheng – sequence: 3 givenname: Yu-Wen surname: Wen fullname: Wen, Yu-Wen – sequence: 4 givenname: Chien-Yu surname: Lin fullname: Lin, Chien-Yu – sequence: 5 givenname: Kang-Hsing surname: Fan fullname: Fan, Kang-Hsing – sequence: 6 givenname: Jin-Ching surname: Lin fullname: Lin, Jin-Ching – sequence: 7 givenname: Shu-Hang surname: Ng fullname: Ng, Shu-Hang – sequence: 8 givenname: Shu-Ru surname: Lee fullname: Lee, Shu-Ru – sequence: 9 givenname: Chung-Jan surname: Kang fullname: Kang, Chung-Jan – sequence: 10 givenname: Li-Yu surname: Lee fullname: Lee, Li-Yu – sequence: 11 givenname: Chih-Yen surname: Chien fullname: Chien, Chih-Yen – sequence: 12 givenname: Chun-Hung surname: Hua fullname: Hua, Chun-Hung – sequence: 13 givenname: Cheng Ping surname: Wang fullname: Wang, Cheng Ping – sequence: 14 givenname: Tsung-Ming surname: Chen fullname: Chen, Tsung-Ming – sequence: 15 givenname: Shyuang-Der surname: Terng fullname: Terng, Shyuang-Der – sequence: 16 givenname: Chi-Ying surname: Tsai fullname: Tsai, Chi-Ying – sequence: 17 givenname: Hung-Ming surname: Wang fullname: Wang, Hung-Ming – sequence: 18 givenname: Chia-Hsun surname: Hsieh fullname: Hsieh, Chia-Hsun – sequence: 19 givenname: Chih-Hua surname: Yeh fullname: Yeh, Chih-Hua – sequence: 20 givenname: Chih-Hung surname: Lin fullname: Lin, Chih-Hung – sequence: 21 givenname: Chung-Kan surname: Tsao fullname: Tsao, Chung-Kan – sequence: 22 givenname: Nai-Ming surname: Cheng fullname: Cheng, Nai-Ming – sequence: 23 givenname: Tuan-Jen surname: Fang fullname: Fang, Tuan-Jen – sequence: 24 givenname: Shiang-Fu surname: Huang fullname: Huang, Shiang-Fu – sequence: 25 givenname: Li-Ang surname: Lee fullname: Lee, Li-Ang – sequence: 26 givenname: Ku-Hao surname: Fang fullname: Fang, Ku-Hao – sequence: 27 givenname: Yu-Chien surname: Wang fullname: Wang, Yu-Chien – sequence: 28 givenname: Wan-Ni surname: Lin fullname: Lin, Wan-Ni – sequence: 29 givenname: Li-Jen surname: Hsin fullname: Hsin, Li-Jen – sequence: 30 givenname: Tzu-Chen surname: Yen fullname: Yen, Tzu-Chen – sequence: 31 givenname: Chun-Ta surname: Liao fullname: Liao, Chun-Ta |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39456017$$D View this record in MEDLINE/PubMed |
| BookMark | eNptk11v0zAUhiM0xD7gD3CBLCEhuMiwEydxuEHTxMekSSAY19aJc5y6Su3Odlb6o_iPuO0YLSKRYsd-_ER57XOaHVlnMcueM3rOmKjfBlYIUeW04DkrKRc5e5SdMN6wvOC0OdrrH2enIcwpZY2g4kl2XLa8qtPbSfbrq3eDdSEaRYIZrNFGgVVInCbQz6c7sJHEGXpYrgnYnoQlqg1EPPQGonGW9C7AgIEYS27ArMBiQLJMc2hjICsTZ8R5GImCOxPXZOv3Wxn-jB5y6_o0m_poQ_K9I0Ds1rwyPRLlZs5HEuLUr59mjzWMAZ_dt2fZj48fbi4_59dfPl1dXlznqhI05l3bdFTVAnSH2DaiQq5LzTslBEtXw5ByqGmva051UZZcQN0JgVSA0Cja8iy72nl7B3O59GYBfi0dGLkdcH6Q4FNkI0qsoNRY1GVHK85YC9iKvu94LVTdFFWVXO93ruXULbBXKZQUxoH0cMaamRzcnWSsYhVtN4bX9wbvbicMUS5MUDiOKWk3BVmygtFKNGWR0Jf_oHM3eZuy2lA1TyeiaP9SA6Q_MFa79GG1kcoLwcq6LQQXiTr_D5XuHhdGpaOoTRo_WPDmYEFiYtrVAaYQ5NX3b4fsqz12hjDGWXDjtNn2cAi-2I_vIbc_RzgBxQ5Q3oXgUT8gjMpNnchdnchUJ3JbJ-n5Gx26Be0 |
| Cites_doi | 10.1016/j.oraloncology.2018.09.021 10.1038/sj.bjc.6602678 10.1002/1097-0142(19900701)66:1<109::AID-CNCR2820660120>3.0.CO;2-A 10.1111/jop.12870 10.1016/j.ijrobp.2010.07.1988 10.1002/cam4.3883 10.3389/fonc.2021.754412 10.1200/JCO.2016.68.2336 10.1016/0021-9681(87)90171-8 10.1016/j.oraloncology.2005.05.008 10.1007/s00259-019-04453-x 10.1056/NEJMoa032646 10.1093/aje/154.9.854 10.1016/j.oraloncology.2020.105169 10.1002/1097-0142(20011215)92:12<3030::AID-CNCR10148>3.0.CO;2-P 10.1186/s12885-022-09393-8 10.1002/lary.27508 10.1002/hed.26499 10.1002/cam4.1611 10.1002/hed.20279 10.1093/jnci/djy088 10.1002/lary.30158 10.1056/NEJMoa032641 10.1016/j.oraloncology.2020.104845 10.1016/j.oraloncology.2015.11.010 10.1016/j.oraloncology.2023.106366 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12885-024-13048-1 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_e5a3fe263b054119ae98ddb468c67255 PMC11515095 A813692848 39456017 10_1186_s12885_024_13048_1 |
| Genre | Journal Article |
| GeographicLocations | Taiwan |
| GeographicLocations_xml | – name: Taiwan |
| GrantInformation_xml | – fundername: Chang Gung Memorial Hospital, Linkou grantid: CMRPD1H0521 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 LGEZI LOTEE M1P M48 M~E NADUK NXXTH O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c580t-b97b0c68afbee9785e4f3f4bc88111171e04a60df640f23348a6b88e08a8fe893 |
| IEDL.DBID | M48 |
| ISSN | 1471-2407 |
| IngestDate | Wed Aug 27 01:17:43 EDT 2025 Thu Aug 21 18:44:09 EDT 2025 Thu Jul 10 19:17:08 EDT 2025 Sat Jul 26 00:19:31 EDT 2025 Tue Jun 17 22:02:12 EDT 2025 Tue Jun 10 21:01:06 EDT 2025 Fri Jun 27 05:26:37 EDT 2025 Thu May 22 21:24:28 EDT 2025 Mon Jul 21 06:00:03 EDT 2025 Tue Jul 01 04:29:49 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Survival outcomes Extra-nodal extension Cancer registry Radiotherapy Chemoradiotherapy Oral cavity squamous cell carcinoma |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c580t-b97b0c68afbee9785e4f3f4bc88111171e04a60df640f23348a6b88e08a8fe893 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12885-024-13048-1 |
| PMID | 39456017 |
| PQID | 3126414729 |
| PQPubID | 44074 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e5a3fe263b054119ae98ddb468c67255 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11515095 proquest_miscellaneous_3121058732 proquest_journals_3126414729 gale_infotracmisc_A813692848 gale_infotracacademiconefile_A813692848 gale_incontextgauss_ISR_A813692848 gale_healthsolutions_A813692848 pubmed_primary_39456017 crossref_primary_10_1186_s12885_024_13048_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-10-25 |
| PublicationDateYYYYMMDD | 2024-10-25 |
| PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | ME Charlson (13048_CR17) 1987; 40 CY Chien (13048_CR18) 2023; 140 J Tasoulas (13048_CR20) 2021; 10 JP Agarwal (13048_CR26) 2019; 129 JP Shah (13048_CR1) 1990; 66 CT Liao (13048_CR5) 2011; 81 K Joshi (13048_CR22) 2023; 133 (13048_CR8) 2017 AE Pilborough (13048_CR24) 2019; 48 CT Liao (13048_CR4) 2018; 86 DM Trifiletti (13048_CR21) 2017; 35 CN Abdel-Halim (13048_CR29) 2021; 114 T Mucke (13048_CR7) 2016; 53 JA Woolgar (13048_CR2) 2006; 42 J Bernier (13048_CR10) 2004; 350 I Arun (13048_CR27) 2021; 43 13048_CR9 CT Liao (13048_CR19) 2020; 47 J Bernier (13048_CR3) 2005; 27 YJ Cheng (13048_CR12) 2018; 7 YT Tsai (13048_CR25) 2021; 11 Y Noda (13048_CR23) 2022; 22 W Sauerbrei (13048_CR13) 2018; 110 LM McShane (13048_CR14) 2005; 93 JS Cooper (13048_CR11) 2004; 350 JN Myers (13048_CR6) 2001; 92 S Schneeweiss (13048_CR16) 2001; 154 13048_CR15 JR de Almeida (13048_CR28) 2020; 110 |
| References_xml | – volume: 86 start-page: 188 year: 2018 ident: 13048_CR4 publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2018.09.021 – volume: 93 start-page: 387 year: 2005 ident: 13048_CR14 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602678 – volume: 66 start-page: 109 year: 1990 ident: 13048_CR1 publication-title: Cancer doi: 10.1002/1097-0142(19900701)66:1<109::AID-CNCR2820660120>3.0.CO;2-A – volume: 48 start-page: 863 year: 2019 ident: 13048_CR24 publication-title: J Oral Pathol Med doi: 10.1111/jop.12870 – volume: 81 start-page: 930 year: 2011 ident: 13048_CR5 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.07.1988 – volume: 10 start-page: 3231 year: 2021 ident: 13048_CR20 publication-title: Cancer Med doi: 10.1002/cam4.3883 – volume: 11 start-page: 754412 year: 2021 ident: 13048_CR25 publication-title: Front Oncol doi: 10.3389/fonc.2021.754412 – volume: 35 start-page: 1550 year: 2017 ident: 13048_CR21 publication-title: J Clin Oncol doi: 10.1200/JCO.2016.68.2336 – volume: 40 start-page: 373 year: 1987 ident: 13048_CR17 publication-title: J Chronic Dis doi: 10.1016/0021-9681(87)90171-8 – volume: 42 start-page: 229 year: 2006 ident: 13048_CR2 publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2005.05.008 – volume: 47 start-page: 84 year: 2020 ident: 13048_CR19 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-019-04453-x – volume: 350 start-page: 1937 year: 2004 ident: 13048_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMoa032646 – volume: 154 start-page: 854 year: 2001 ident: 13048_CR16 publication-title: Am J Epidemiol doi: 10.1093/aje/154.9.854 – volume: 114 start-page: 105169 year: 2021 ident: 13048_CR29 publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2020.105169 – volume: 92 start-page: 3030 year: 2001 ident: 13048_CR6 publication-title: Cancer doi: 10.1002/1097-0142(20011215)92:12<3030::AID-CNCR10148>3.0.CO;2-P – volume: 22 start-page: 402 year: 2022 ident: 13048_CR23 publication-title: BMC Cancer doi: 10.1186/s12885-022-09393-8 – volume: 129 start-page: 1130 year: 2019 ident: 13048_CR26 publication-title: Laryngoscope doi: 10.1002/lary.27508 – ident: 13048_CR15 – volume: 43 start-page: 520 year: 2021 ident: 13048_CR27 publication-title: Head Neck doi: 10.1002/hed.26499 – volume: 7 start-page: 3073 year: 2018 ident: 13048_CR12 publication-title: Cancer Med doi: 10.1002/cam4.1611 – volume: 27 start-page: 843 year: 2005 ident: 13048_CR3 publication-title: Head Neck doi: 10.1002/hed.20279 – volume-title: AJCC cancer staging manual year: 2017 ident: 13048_CR8 – volume: 110 start-page: 803 year: 2018 ident: 13048_CR13 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djy088 – volume: 133 start-page: 588 year: 2023 ident: 13048_CR22 publication-title: Laryngoscope doi: 10.1002/lary.30158 – volume: 350 start-page: 1945 year: 2004 ident: 13048_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMoa032641 – volume: 110 start-page: 104845 year: 2020 ident: 13048_CR28 publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2020.104845 – volume: 53 start-page: 80 year: 2016 ident: 13048_CR7 publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2015.11.010 – ident: 13048_CR9 – volume: 140 start-page: 106366 year: 2023 ident: 13048_CR18 publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2023.106366 |
| SSID | ssj0017808 |
| Score | 2.4256256 |
| Snippet | The evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in National Comprehensive... Background The evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in National... BackgroundThe evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in National... Abstract Background The evidence for adjuvant chemoradiotherapy (CRT) of oral cavity squamous cell carcinoma (OCSCC) with extra-nodal extension (ENE) in... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1320 |
| SubjectTerms | Adjuvant therapy Adjuvant treatment Adult Aged Cancer Cancer registry Cancer therapies Care and treatment Chemoradiotherapy Chemoradiotherapy, Adjuvant - methods Chemotherapy Comorbidity Development and progression Diagnosis Disease Dosage Drug dosages Extra-nodal extension Extranodal Extension Female Head & neck cancer Head and neck cancer Humans Lymphatic metastasis Lymphatic system Male Medical prognosis Metastasis Middle Aged Mouth Neoplasms - mortality Mouth Neoplasms - pathology Mouth Neoplasms - radiotherapy Mouth Neoplasms - therapy Oncology Oral carcinoma Oral cavity Oral cavity squamous cell carcinoma Patient outcomes Patients Prognosis Radiation Radiation therapy Radiotherapy Radiotherapy Dosage Retrospective Studies Review boards Risk factors Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck - mortality Squamous Cell Carcinoma of Head and Neck - radiotherapy Squamous Cell Carcinoma of Head and Neck - therapy Surgery Survival outcomes Taiwan - epidemiology |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9QwDI7QHhAXxJvCAgYhcUDR9pEmHm4LYrUgLUKwK-0tSpsUhkOL2o5W_Cj-I3baGU3FgQvXsaeaiR37c2p_EeIlFunK1MbICj1KVWslnTFeZiF3pUetjeHZ4bNP-vRCfbwsL_eu-uKesIkeeFq4o1C6ogm5LioCF1nGXNLofaU01toQHuboSzlvW0zN7w8MprgdkUF9NFAURp5EVpJitqK6aZGGIlv_3zF5LyktGyb3MtDJLXFzho5wPP3k2-JaaO-I62fzy_G74vfnvuO2ORIDt2VwExDbFLoGnP-xIcw8wjRv9Qtc64GnLFkJeiYoYAuB77jRbIB1C-dufeX4fkqYuVcH4ENb4JF-qB3fOQHx-X18GAX53sm28ySNJ-t8DPcGHEzHjVdrH4Bv4-1HiJS298TFyfvzd6dyvo1B1iWmo6xWpkprja6pQqDaswyqKRpV1Ygcdk0WUuV06hut0ibnAV-nK8SQosMmECy6Lw7arg0PBRCESsuakJDzSjU6uAIpSZrCKeUJTpSJeL01jv05kW7YWKygtpMpLZnSRlPaLBFv2X47TSbMjh-QG9nZjey_3CgRz9j6dpo-3W17e4xZoVeUwzERL6IGk2a03JXzzW2GwX74-mWh9GpWajpa9drNQw70v5lna6F5uNCkXV0vxVs3tHNUGWyREXzNFNVDiXi-E_M3uVOuDd0m6hBkRlPkiXgwee1uZYqV4gLcJAIX_rxYuqWkXX-PnOMZA1-C44_-x2I_FjfyuBdTmZeH4mDsN-EJYbuxehq38R8AKU1f priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA9aQXwRv12tGkXwQUL3I5vM-SJVLFWoiLbQt5BNsvV82K27dxT_KP9HZ7K5s4vg683ccpfJzPxmdj4YewlVvtBOa9GAByGdksJq7UURSlt7UEpr6h0--qwOT-Sn0_o0JdzGVFa5sYnRUPveUY58ryrQdRcSseDb85-CtkbR29W0QuMqu0ajy-hW69NtwFVoyGHTKANqb0RbDNSPLAVabonR08wZxZn9_1rmS65pXjZ5yQ8d3GI3E4Dk-5PEb7MrobvDrh-lV-R32e8vQ0_Fc0jmVJxBpUAkWd633Pofa0TOKz51Xf3itvOcei2JiQ80poDkxH1P5WYjX3b82C4vLG2p5GkC68gpdcupsZ87S5sneHz-EB-Gpn6wous9UmN-nZJxb7jlU9LxYukDp528w4rHwbb32MnBh-P3hyLtZBCuhnwlmoVucqfAtk0IGIHWQbZVKxsHQMZXFyGXVuW-VTJvS2rztaoBCDlYaAOCo_tsp-u78JBxBFJ57RAPWS9lq4KtAF2lrqyUHkFFnbHXG-GY82n0hokhCygzidKgKE0UpSky9o7kt-Wksdnxg344M0kLTaht1YZSVQ0iVbwxNizA-0YqcEpjcJWxZyR9M_WgbpXf7ENRqQV6csjYi8hBozM6qs05s-txNB-_fZ0xvUpMbY-n7mxqdcD_TdO2Zpy7M07UbTcnb66hSbZlNH81IWPPt2T6JtXLdaFfRx4EzqCrMmMPplu7PZlqISkM1xmD2X2eHd2c0i2_x8njBcFfBOWP_v-7HrMbZdSyXJT1LttZDevwBLHbqnkaFfQPs7ZFFw priority: 102 providerName: ProQuest |
| Title | Prognostic significance of adjuvant therapy and specific radiation dosages in Taiwanese patients with oral cavity cancer and extra-nodal extension: a nationwide cohort study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39456017 https://www.proquest.com/docview/3126414729 https://www.proquest.com/docview/3121058732 https://pubmed.ncbi.nlm.nih.gov/PMC11515095 https://doaj.org/article/e5a3fe263b054119ae98ddb468c67255 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA_3AeKL-G31XKMIPki9fqTJrCByK3ecwh7HeguLLyFt0nNFWu3uct4f5f_oTNpdr3gPvvShmQaaycz8JpkPxl5CGg1VoVSYg4VQFFKERikbxi4xmQUplaLc4fGJPJ6KT7NstsXW7Y66BVxc69pRP6lp8_3Nr5-X71Hg33mBB7m_QB0LlGcsQtTIAr2ibbaLlklRR4Ox-HuroMB3qItRIdOtglon0Vw7R89Q-Xr-_2rtK2arH1J5xUYd3Wa3OnDJD9rdcIdtueouuzHurs_vsd-nTU2BdTjMKXCDwoSI67wuubHfVoiql7zNyLrkprKc8jCJiDdUwoB4yG1NoWgLPq_4mZlfGOpgybvqrAtOx7qckv55YagrBffzN34yNAONCava4qg_e6eDurfc8PZA8mJuHad-vc2S-6K399n06PDsw3HY9WsIiwyiZZgPVR4VEkyZO4feaeZEmZYiLwBIMavYRcLIyJZSRGVCKcBG5gAuAgOlQ-D0gO1UdeUeMY4gK8oKxErGClFKZ1JAM6pSI4RFwJEF7PWaOfpHW5ZDe3cGpG5ZqZGV2rNSxwEbEf82lFRS27-om3PdSah2mUlLl8g0RxQbx1S0HKzNhYRCKnS8AvaMuK_b_NSNYtAHEKdyiFYeAvbCU1BZjYrids7NarHQHz9PekSvOqKyxlUvTJcGgf9Nlbh6lHs9SpT7oj-83oZ6LTY6jRHg4v5OhgF7vhmmLymWrnL1ytMgqAaVJgF72O7azcqkQ0EuugoY9PZzb-n6I9X8q69KHhM0RsD--L9_8Am7mXiBi8Ik22M7y2blniLEW-YDtq1masB2R4cnp5OBPygZeFnG52T05Q9qQ1LL |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgEXxJtAoQaBOKCoeTj2LBJC5VG1tFsh2Eq9GSd2ynJISrKrqj8KfiMzTrI0QuLW63o22vWMZ75xZr5h7Dmk0UQVSoU5WAhFIUVolLJh7BKTWZBSKeodnh7K3SPx6Tg7XmO_h14YKqscfKJ31LYu6I58K40xdMcCseDb058hTY2it6vDCI3OLPbd-RmmbO2bvQ-o3xdJsvNx9n437KcKhEUG0SLMJyqPCgmmzJ3DHCpzokxLkRcA5D5U7CJhZGRLKaIyoUZVI3MAF4GB0gGRL6HLv4KBN6JkTx2vErxYQQRDYw7IrRZ9P1D_swgxUgjM1kbBz88I-DcSXAiF4zLNC3Fv5ya70QNWvt1Z2C225qrb7Oq0fyV_h_363NRUrIfLnIpBqPSILInXJTf2xxKR-oJ3XV7n3FSWU28nCfGGaBHILritqbyt5fOKz8z8zNBUTN4zvracroo5EQnwwtCkC-6f3_iHYWhpTFjVFlf9fT5d_r3mhneXnGdz6zjNAG4W3BPp3mVHl6Kte2y9qiv3gHEEblFWIP4yVohSOpMChmaVGiEsgpgsYK8G5ejTjupD-xQJpO5UqVGV2qtSxwF7R_pbSRJNt_-gbk50f-q1y0xaukSmOSLjOCYidLA2FxIKqTCZC9gmaV93Pa8rZ6O3IU7lBJEDBOyZlyCqjopqgU7Msm313tcvI6GXvVBZ464Xpm-twP9N7F4jyY2RJPqSYrw8mKHufVmr_568gD1dLdM3qT6vcvXSyyBQB5UmAbvfWe1qZ9KJoLRfBQxG9jzauvFKNf_umc5jgtuYBDz8_-_aZNd2Z9MDfbB3uP-IXU_8iYvCJNtg64tm6R4jblzkT_xh5ezbZXuHP3pmgeQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+significance+of+adjuvant+therapy+and+specific+radiation+dosages+in+Taiwanese+patients+with+oral+cavity+cancer+and+extra-nodal+extension%3A+a+nationwide+cohort+study&rft.jtitle=BMC+cancer&rft.au=Tsai%2C+Yao-Te&rft.au=Chen%2C+Wen-Cheng&rft.au=Wen%2C+Yu-Wen&rft.au=Lin%2C+Chien-Yu&rft.date=2024-10-25&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=24&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-024-13048-1&rft.externalDocID=A813692848 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |